Hong Yan

Hong Yan

Auto-generated profile, based on publicly available information

Hong Yan

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YMYanling Ma
Yanling Ma
WWWenyi Wang
Wenyi Wang
JZJie Zhang
Jie Zhang
YLYouli Lu
Youli Lu
WWWenyu Wu
Wenyu Wu
YWYiping Wang
Yiping Wang
Mice deficient in the LDL receptor (Ldlr−/− mice) have been widely used as a model to mimic human atherosclerosis. However, the time-course of atherosclerotic lesion development and distribution of lesions at specific time-points are yet to be established. The current study sought to determine the progression and distribution of lesions in Ldlr−/− mice. Ldlr-deficient mice fed regular chow or a high-fat (HF) diet for 0.5 to 12 months were analyzed for atherosclerotic lesions with en face and cross-sectional imaging. Mice displayed significant individual differences in lesion development when fed a chow diet, whereas those on a HF diet developed lesions in a time-dependent and site-selective manner. Specifically, mice subjected to the HF diet showed slight atherosclerotic lesions distributed exclusively in the aortic roots or innominate artery before 3 months. Lesions extended to the thoracic aorta at 6 months and abdominal aorta at 9 months. Cross-sectional analysis revealed the presence of advanced lesions in the aortic sinus after 3 months in the group on the HF diet and in the innominate artery at 6 to 9 months. The HF diet additionally resulted in increased total cholesterol, LDL, glucose, and HBA1c levels, along with the complication of obesity. Ldlr-deficient mice on the HF diet tend to develop site-selective and size-specific atherosclerotic lesions over time. The current study should provide information on diet induction or drug intervention times and facilitate estimation of the appropriate locations of atherosclerotic lesions in Ldlr−/− mice.

20 March 2013 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
WWWen‐Yu Wu
Wen‐Yu Wu
WWWen‐Yi Wang
Wen‐Yi Wang
YMYan‐Ling Ma
Yan‐Ling Ma
HYHong Yan
Hong Yan
XWXin‐Bo Wang
Xin‐Bo Wang
YWYi‐Ping Wang
Yi‐Ping Wang
Background and Purpose: Inhibition of apoptosis may attenuate the irreversible injury associated with reperfusion. In the current study, we focused on the cytoprotective effects and the underlying mechanism of sodium tanshinone IIA silate (STS) against damage induced by oxygen‐glucose deprivation/recovery (OGD/R). in H9c2 cardiomyocytes and the underlying mechanisms.Experimental Approach: We used a model of cardiac ischaemia/reperfusion, OGD/R in H9c2 cardiomyocytes, to assess the cardioprotective effects of STS. Apoptosis of cells was measured with Hoechst 33342‐based fluorescence microscopy, and annexin V‐FITC‐based flow cytometry. Caspase‐3 and caspase‐8 activities and mitochondrial membrane potential were also measured using commercial kits. TNF‐α in the cell culture supernatant fractions were measured with sandwich elisa, and protein levels assayed using Western blot.Key Results: STS inhibited OGD/R‐induced apoptosis by suppressing JNK‐mediated activation of NF‐κB, TNF‐α expression, activation of caspase‐3 and caspase‐8 and the Bax/Bcl‐2 ratio. Additionally, positive feedback between NF‐κB and TNF‐α and amplification of TNF‐α were inhibited, suggesting that STS plays a protective role against apoptosis in cardiomyocytes, even upon activation of pro‐inflammatory cytokines. Interestingly, the cytoprotective effects of STS on OGD/R‐induced apoptosis and promotion of cell survival were attenuated after inhibition of PI3K.Conclusion and Implications: The inhibitory effects of STS on TNF‐α and positive feedback signalling of the NF‐κB/TNF‐α pathways may play important roles in myocardial protection against ischaemia/reperfusion. These protective effects of STS are mediated by suppressing JNK activity through activation of the PI3K‐Akt pathway.

16 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WWWen-Yu Wu
Wen-Yu Wu
HYHong Yan
Hong Yan
XWXin-Bo Wang
Xin-Bo Wang
YGYu-Zhou Gui
Yu-Zhou Gui
FGFei Gao
Fei Gao
YWYi-Ping Wang
Yi-Ping Wang
The proliferation of vascular smooth muscle cells may perform a crucial role in the pathogenesis of diabetic vascular disease. AMPK additionally exerts several salutary effects on vascular function and improves vascular abnormalities. The current study sought to determine whether sodium tanshinone IIA silate (STS) has an inhibitory effect on vascular smooth muscle cell (VSMC) proliferation and migration under high glucose conditions mimicking diabetes without dyslipidemia, and establish the underlying mechanism. In this study, STS promoted the phosphorylation of AMP-activated protein kinase (AMPK) at T172 in VSMCs. VSMC proliferation was enhanced under high glucose (25 mM glucose, HG) versus normal glucose conditions (5.5 mM glucose, NG), and this increase was inhibited significantly by STS treatment. We utilized western blotting analysis to evaluate the effects of STS on cell-cycle regulatory proteins and found that STS increased the expression of p53 and the Cdk inhibitor, p21, subsequent decreased the expression of cell cycle-associated protein, cyclin D1. We further observed that STS arrested cell cycle progression at the G0/G1 phase. Additionally, expression and enzymatic activity of MMP-2, translocation of NF-κB, as well as VSMC migration were suppressed in the presence of STS. Notably, Compound C (CC), a specific inhibitor of AMPK, as well as AMPK siRNA blocked STS-mediated inhibition of VSMC proliferation and migration. We further evaluated its potential for activating AMPK in aortas in animal models of type 2 diabetes and found that Oral administration of STS for 10 days resulted in activation of AMPK in aortas from ob/ob or db/db mice. In conclusion, STS inhibits high glucose-induced VSMC proliferation and migration, possibly through AMPK activation. The growth suppression effect may be attributable to activation of AMPK-p53-p21 signaling, and the inhibitory effect on migration to the AMPK/NF-κB signaling axis.

31 August 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WWWen-Yi Wang
Wen-Yi Wang
JZJie Zhang
Jie Zhang
WWWen-Yu Wu
Wen-Yu Wu
JLJie Li
Jie Li
YMYan-Ling Ma
Yan-Ling Ma
YWYi-Ping Wang
Yi-Ping Wang
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is thought to play modulatory roles in the development of atherosclerosis. Here we evaluated the effects of a specific lp-PLA2 inhibitor on atherosclerosis in ApoE-deficient mice and its associated mechanisms. ApoE-deficient mice fed an atherogenic high-fat diet for 17 weeks were divided into two groups. One group was administered the specific lp-PLA2 inhibitor, darapladib (50 mg/kg/day; p.o.) daily for 6 weeks, while the control group was administered saline. We observed no differences in body weight and serum lipids levels between the two groups at the end of the dietary period. Notably, serum lp-PLA2 activity as well as hs-CRP (C-reactive protein) and IL-6 (Interleukin-6) levels were significantly reduced in the darapladib group, compared with the vehicle group, while the serum PAF (platelet-activating factor) levels were similar between the two groups. Furthermore, the plaque area through the arch to the abdominal aorta was reduced in the darapladib group. Another finding of interest was that the macrophage content was decreased while collagen content was increased in atherosclerotic lesions at the aortic sinus in the darapladib group, compared with the vehicle group. Finally, quantitative RT-PCR performed to determine the expression patterns of specific inflammatory genes at atherosclerotic aortas revealed lower expression of MCP-1, VCAM-1 and TNF-α in the darapladib group. Inhibition of lp-PLA2 by darapladib leads to attenuation of in vivo inflammation and decreased plaque formation in ApoE-deficient mice, supporting an anti-atherogenic role during the progression of atherosclerosis.

4 July 2016 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
YGYu-Zhou Gui
Yu-Zhou Gui
HYHong Yan
Hong Yan
FGFei Gao
Fei Gao
CXCong Xi
Cong Xi
HLHui-Hui Li
Hui-Hui Li
YWYi-Ping Wang
Yi-Ping Wang

21 July 2014 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
HYHong Yan
Hong Yan
YMYan-Ling Ma
Yan-Ling Ma
YGYu-Zhou Gui
Yu-Zhou Gui
SWShu-Mei Wang
Shu-Mei Wang
XWXin-Bo Wang
Xin-Bo Wang
YWYi-Ping Wang
Yi-Ping Wang
Expression of liver low-density lipoprotein receptor (LDLR), a determinant regulator in cholesterol homeostasis, is tightly controlled at multiple levels. The aim of this study was to examine whether proteasome inhibition could affect LDLR expression and LDL uptake in liver cells in vitro. HepG2 cells were examined. Real-time PCR and Western blot analysis were used to determine the mRNA and protein levels, respectively. DiI-LDL uptake assay was used to quantify the LDLR function. Luciferase assay system was used to detect the activity of proprotein convertase subtilisin/kexin type 9 (PCSK9, a major protein mediating LDLR degradation) promoter. Specific siRNAs were used to verify the involvement of PCSK9. Treatment of HepG2 cells with the specific proteasome inhibitor MG132 (0.03–3 μmol/L) dose-dependently increased LDLR mRNA and protein levels, as well as LDL uptake. Short-term treatment with MG132 (0.3 μmol/L, up to 8 h) significantly increased both LDLR mRNA and protein levels in HepG2 cells, which was blocked by the specific PKC inhibitors GF 109203X, Gö 6983 or staurosporine. In contrast, a longer treatment with MG132 (0.3 μmol/L, 24 h) did not change LDLR mRNA, but markedly increased LDLR protein by reducing PCSK9-mediated lysosome LDLR degradation. Furthermore, MG132 time-dependently suppressed PCSK9 expression in the HepG2 cells through a SREBP-1c related pathway. Combined treatment with MG132 (0.3 μmol/L) and pravastatin (5 μmol/L) strongly promoted LDLR expression and LDL uptake in HepG2 cells, and blocked the upregulation of PCSK9 caused by pravastatin alone. Inhibition of proteasome by MG132 in HepG2 cells plays dual roles in LDLR and PCSK9 expression, and exerts a beneficial effect on cholesterol homeostasis.